Ownership history in PAULSON & CO. INC. Β· 11 quarters on record
This page tracks every 13F SEC filing in which PAULSON & CO. INC. reported a position in MADRIGAL PHARMACEUTICALS INC (MDGL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π PAULSON & CO. INC. outperformed the S&P 500 by +36.7% annually on this MDGL position. Timing score: 44% (4/9 decisions correct). Average cost basis: $239.32. Maximum drawdown during holding period: β36.8%.
π₯ Exceptional β beat the S&P 500 by 36.7% per year on this position.
10 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
4 of 9 add/trim decisions correct
Best entry: $146.04 (2023 Q3) Β· Worst: $331.23 (2025 Q1)
πͺ Held through 2 major drawdowns (>20%).
7 adds Β· 3 trims. Bought during 2 of 3 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 30.48% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size